



Periscope  
BioScience

Enriching the human experience by bringing plant-based medicines to the world.

Investor Presentation

February 2022

# Disclaimer

Information contained in this presentation is the property of Periscope Bioscience Corp. ("Periscope" or the "Company"). This presentation does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company, nor shall it, or the fact of its communication, form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment whatsoever with respect to such securities. The communication of this presentation in or to persons in certain jurisdictions may be restricted by law and persons who may receive communication of this presentation should inform themselves about and observe any such restrictions in advance of communication to them of this presentation. No securities exchange or affiliated service provider has reviewed or accepts responsibility for the adequacy or accuracy of the content of this presentation.

The material contained in this presentation is provided solely for your general knowledge and is not intended to be a comprehensive review of all matters concerning Periscope or its affiliates. The Company has taken all reasonable care in producing the information contained in this presentation. This information may contain technical or other inaccuracies, omissions, or typographical errors, for which Periscope assumes no responsibility. Periscope makes no representation or warranty regarding, and assumes no responsibility for, the use, validity, accuracy, completeness, reliability or currency of any claims, statements or information in this presentation.

To the extent permitted by law, Periscope and its employees, agents, affiliates and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission. Statements in this presentation other than purely historical information, including statements relating to Periscope future plans, objectives or expected results, constitute forward-looking statements within the meaning of U.S. federal and Canadian securities laws. Forward-looking statements are based on numerous assumptions and are subject to the risks and uncertainties inherent in Periscope business, including risks inherent in early to development stage start-up ventures. These may include the state of the emerging legal cannabis and psychedelics sectors, global market conditions, the ability of the Company to identify and acquire key assets, the nature of potential business acquisitions, capital expenditures, successful development of technologies, currency fluctuations, government policy and regulation, geopolitical uncertainty and environmental regulation. As a result, actual results may vary materially from those described in the forward-looking statements. Periscope disclaims any obligation to update any forward-looking statements.

This presentation was prepared to assist interested parties in making their own assessment of Periscope and its business plans and does not purport to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company, its assets and the information provided in this presentation. Any and all statements, forecasts, projections and estimates contained in this presentation are based on management's current knowledge and no representation or warranty is made as to their accuracy and/or reliability.

# Our Vision

Periscope was established to identify and exploit global market opportunities in the new plant based medical economy.

As a vertically integrated company with pharma grade (eu-GMP) manufacturing capabilities + ability to distribute medication globally Periscope is in a position to bring leading evidence- based plant medicine and psychedelic treatment options forward globally.

# Pain Points

- Over the past few years there has been rapid growth in mainstream acceptance of plant-based medicines as evidence-based treatments for a variety of health and wellness concerns similar to traditional pharmaceuticals.
- A minimum standard of manufacturing quality known as Good Manufacturing Practices (eu-GMP) has been established as the gold standard, much as it is with traditional pharma manufacturing.
- The problem is that many companies around the world did not build their facilities to the standard.
- Retrofitting or upgrading is either not possible, cost prohibitive, and very time consuming. As a result, these companies are stranded, and unable to offer their plant-based medicines to key global markets.

**Periscope is the solution to these issues.**

# Solution

- Periscope is comprised of a leading team of medical professionals, engineers, scientists, formulators, and extractors with substantial expertise covering everything from seed to shelf in the production of plant-based medicines.
- Periscope has supply contracts in place with leading LP's in Canada, Africa, and Jamaica to provide a stable supply of high-quality low-cost Cannabinoid and Phycobilin raw product for processing into eu-GMP compliant pharma product.
- Periscope has sales and distribution contracts in place with top tier pharmaceutical channels to purchase our product at set prices providing a back-to-back sales cycle making us highly profitable and scalable.
- Periscope will utilize state of the art manufacturing and processing technology allowing us to offer best in class manufacturing of products for both the medical and consumer markets globally.
- Periscope's partner in Malta has received permission from Malta Enterprise to renovate an existing 12,000 square foot facility in Valetta, Malta into an EU-GMP certifiable facility which will facilitate pharmaceutical grade manufacturing of plant-based medicine.
- **This facility will provide a springboard into the European Union and other key global markets for our products and those of other companies under "value added fee" agreements.**

# Market Data

**\$28.6B**

Global Antidepressants market

**\$78.7B**

Global sleep aids market

**\$10.6B**

Global PTSD treatment market

**\$31.1B**

Global Substance abuse treatment market

Psychedelics and plant-based medicine are currently the leading area of focus for developing more effective treatments for mental health and addictions.

**\$10.75B**

Projected value of the global psychedelics market by 2027

**\$40B**

Projected value of the global plant-based drug market by 2022

# The regulatory and public opinion around psychedelics is changing.

Government and regulatory bodies are starting to recognize the therapeutic benefits of psychedelics, especially in their potential for treating mental illness and addictions.

- 2017 FDA grants Breakthrough Therapy designation to MAPS for MDMA-assisted psychotherapy for PTSD
- 2018 Compass Pathways granted second FDA Breakthrough Therapy designation for use of psilocybin targeting treatment-resistant depression
- 2019 Imperial College London launches the world's first Centre for Psychedelics Research and Johns Hopkins opens the Center for Psychedelic and Consciousness Research
- 2020 Health Canada announces Special Access Program revisions to enable legal psychedelic access outside of clinical trials and approves psilocybin therapy for select patients with terminal illness
- 2020 Psychedelics enter and win US state ballots
- 2020 Germany's Federal government approves a Phase 2b study on psilocybin for treatment-resistant depression, the first psilocybin depression study in Germany since the 1970s.
- 2021 Horizons launches the world's first psychedelic ETF


# Focus on European Market

- Europe is behind North America on both the medical and recreational side of Cannabis (Marijuana).
- Canada declared its citizens had the right to Medical Cannabis in 2000 and recreational in 2018. California allowed Medical Marijuana as early as 1996.
- The market trends of various countries that with Medical Cannabis and then turned recreational followed a trend that is beginning to play out in Europe.
- Periscope has the facilities, supply relationships, and distribution channels in place to become a market leader in this region.

# Periscope Advantage

Periscope is building substantial value for its shareholders by focusing on a strategy of:

- Project development + risk managed M&A of synergistic wellness assets in order to exploit down trends in the Cannabis sector and errors of other companies in our space to build a high-quality portfolio of assets at a low input cost.
- Laser focused on generating near-term revenues, on-going profitability, and being a highly scalable platform.
- Strategic positioning to capitalize on the Cannabinoids industry of today, and the psychedelics industry of the future.



# Strategic Partner and Investor The Asana Bio Group Israel

Asana Bio Group has established the only Cannabis focused testing & research laboratory in Jerusalem Biotech Park. It has just received accreditation from the Ministry of Health and is operational under the name of Lumir Lab.

Asana Bio Group is partnered with Clalit Health Services, Israel's largest HMO with 4.5 million patients, and the 2nd largest HMO in the world.

Israel has a large number of on-going Medical Cannabis clinical trials and Asana Group is developing database to document (medically) the various strains of medicinal cannabis; this has never been done before and is being done in collaboration with the leading medical institutes in Israel; Tel Aviv University, Technion and Clalit Health Services.

The Company anticipates that the Asana Bio Group will develop a large demand for Periscope products in Israel.

# Key Milestones

- Developed a dedicated supply line with a Jamaican partner to supply GMP psilocybin which will be exported from Jamaican and imported into Malta for further processing to reach eu-GMP standards.
- Opened its commercial banking facilities.
- Researched and completed due diligence, on its clean room provider from Italy.
- Identified a "Qualified Person" (required) to oversee its commercial operations.
- Identified a facility manager with 10 years in the pharmaceutical manufacturing business.
- Begun initial leasehold improvements of its Malta facility.
- Signed an LOI to purchase Medical Cannabis from supplier in Africa.
- Signed an LOI to be a value add eu-GMP supplier with Canadian Medical Cannabis grower.
- Secured medical, engineering and extraction experts to implement business plan.

# Projected Revenues Generated by Periscope Cannabinoids

Periscope will realize 3 different revenue streams for its Cannabis Flower, at three different price points.

For Third Party Value Add the Company will charge € 1.50 per gram  
 For sales to distributors and importers of the Company's own product € 4.00 per gram  
 92% eu-GMP THC Oil wholesale (distillate) € 6.00 per gram

Year	2022 *	2023**	2024***
Third Party Value Add	€ 375,000	€ 1,500,000	€ 3,000,000
Direct to Distribution	€ 600,000	€ 1,500,000	€ 4,800,000
Extracted oils	-----	€ 1,200,000	€ 2,400,000
<b>Revenues</b>	<b>€ 975,000</b>	<b>€ 4,200,000</b>	<b>€ 10,200,000</b>

# Projected Revenues from Periscope Psilocybin and Drinks

eu-GMP certified pure Psilocybin wholesale  
Bottled health drinks wholesale \*  
Bulk licensing core drink ingredients \*\*

€ 5.00 per gram  
€ 2.00 per bottle  
€ 5,000 per kilo

\* Note: as liquids are heavy and expensive to ship core ingredients will be produced in Jamaica and Malta and shipped bulk to strategic bottling facilities in required continents.

\*\* Bulk drink ingredients will be various combinations of CBD, THC, Psilocybin and other Jamaican specific plants and herbs. Each Kilo of core ingredient should supplement 100,000 of 500ml bottles.

Year	2022	2023	2024
Bulk Psilocybin	€ 900,000	€ 2,000,000	€ 4,000,000
Branded Drinks	€ 200,000	€ 500,000	€ 1,000,000
Bulk Supplement	€ 200,000	€ 500,000	€ 1,000,000
<b>Revenues</b>	<b>€ 1,300,000</b>	<b>€ 3,000,000</b>	<b>€ 6,000,000</b>

# Combined Projected Revenue & EBITDA

Year	2022	2023	2024
Total combined sales	€ 2,750,000	€ 7,200,000	€ 16,200,000
Combined EBITDA	€ 785,730	€ 4,219,400	€ 10,949,400
<i>EBITDA (CAD)</i>	<i>\$ 1,130,339</i>	<i>\$ 6,067,786</i>	<i>\$ 15,746,110</i>

# Team

## **ARTHUR GRIFFITHS** CHAIRMAN AND PRESIDENT

Mr. Griffiths has extensive experience in retail, real estate, civil design, construction, public relations, and international business transactions. He was the Managing Director of BOSCO UK and was Chairman for the Vancouver 2010 Olympic Bid Society. Locally Mr. Griffiths held positions as the youngest owner in NBA and NHL history where he held the position as Owner, Chairman and CEO for Orca Bay Entertainment, which owned the Vancouver Canucks, Vancouver Grizzlies, and where Mr. Griffiths privately financed the design and construction of GM Place (Rogers Arena). He also led the design and construction of the \$1.2 Billion Vancouver Skytrain System as Chairman and Chief Negotiator. Mr. Griffiths and his family are committed to giving back to their community, he is a founding member of Canuck place Children's Hospice, and numerous other charitable boards and most recently has been appointed to be the President of the Vancouver Canucks Alumni foundation board. Mr. Griffiths holds a Bachelor of Business Administration (BBA) focused on marketing and received his Honorary DR of Law in 2011.

## **LAURA CHODOLA** CHIEF STRATEGY OFFICER

A career entrepreneur, Laura is the co-founder and CEO of Tealish, a market-leading Canadian specialty tea company, founded in 2005. She is also the co-founder and Chief Strategy Officer of JOYN Botanicals, a cannabis biotech company with patent-pending technology for water-soluble and highly bioavailable cannabis powder. Laura has created brands and products sold across the continent for some of North America's largest retailers including Macys, Whole Foods, Indigo, Hudson's Bay, Staples, Avon, and Goodfood. With expertise and a history of success creating cutting-edge products in the plant-based wellness sector, Laura's products have garnered attention worldwide. Laura is an astute and motivating leader, and holds an Hons. BA from the University of Toronto, with a major in Psychology and minors in Economics and English.

## **DEREK SHEPHERD** CHIEF EXECUTIVE OFFICER

Mr. Shepherd is a relationship focused leader with a proven track record in international business development and capital markets. Beginning his career in the financial sector as a licensed Investment Advisor focused on high-net worth individuals and private foundations. He later sold his practice to focus on creating a commodity focused investment bank, building this into a global firm with a team footprint in Asia, North America, and Europe before exiting in 2016. Following this he started a private consulting business and served as Global Director of Capital Markets for an international fintech company. Mr. Shepherd has a passion for plant-based medicine, personal wellness, and places a high priority on the need to bring advancements in mental health and addictions to those who need it most. He is an active supporter of organizations related to mental health, addictions, and animal welfare.

## **DR. JAN SPITERI** CHAIRMAN & PRESIDENT (Malta Operations)

Jan qualified as a medical doctor in the UK in 1996; after which he returned to Malta and qualified as a Specialist Registrar in Family Medicine. He is registered on the General Medical Council (UK) & the Malta Medical Council (Malta). Doctor. Spiteri became interested in the benefits of plant based medicines and has been studying the field for many years. Dr. Spiteri was instrumental in lobbying the Maltese government to recognize the value of Medical Cannabis and was one of the first to be issued an LOI from Malta Enterprise to be able to manufacture and sell eu-GMP Cannabinoids globally.

# Team

## **JOSEPH D. ARTISS, PH.D., FACB** SCIENCE ADVISOR

Dr. Artiss is Emeritus Associate Professor of Pathology, Wayne State University with 40 years experience in the healthcare arena. He has a B.Sc. in Biology and Chemistry, M.Sc. and PHD in Clinical Chemistry, and is the author of approximately 70 peer-reviewed original articles, as well as 15 review articles and 8 book chapters. With a track record of breakthrough innovations, he is the inventor or co-inventor of over 60 patents and patent applications. Products developed with these patents have been sold worldwide. Recognized as an expert in his field, he has consulted for numerous major manufacturers during the past four decades and has started and successfully exited several companies, including ones in the natural health products sector.

## **SHEA DE JARAY** CHIEF OPERATIONS MANAGER

Shea is a Queen's University (Toronto Canada) engineering graduate specializing in Mechanical Engineering with a sub specialty in Fluid Dynamics. He has a master of science from Herriot-Watt University specializing in distilling and brewing technologies. Shea has engineered and overseen the installation of high-pressure distillation and brewing systems globally. He is the founder of a successful brewery and distillery in Vancouver Canada called Deep Cove Brewers and Distillers, <http://deepcovecraft.com>. Shea has engineered and overseen the building of 3 extraction facilities, including two of the largest in Europe.

## **TOM VARGA** EXTRACTION CONSULTANT

Tom Varga has been in the extraction and formulation business since 2011. He has been involved in Construction Project Management and Project Coordination of Large-scale projects since the 1980s. Since 2011, he began studying medical cannabis, extraction, and formulation. He is specializing in product formulation using Cannabinoids, Nutra-ceuticals, Terpenes and Essential oils for the past years. He has formulated over 100 products in the medical side of the industry with many delivery aspects. Working with Doctors, Naturopaths, and patients has led to quality medical products. This has led to create efficient Manufacturing and Production systems to for filling and packaging of products. Tom looks forward to being involved with clinical studies and further product development with our advisors. Keeping current in extraction methods and technology has been of great value in the practical design work of our extraction facility. He has worked on numerous extraction facilities in design and fine-tuning the systems and method. He has been responsible in writing SOPs for extraction facilities, products and method of extraction and manufacturing. Tom will be responsible for the management and training of the extraction team.

## **NORMAN SPITERI** ADVISOR

Norman is a fellow of the Institute of Chartered Accountants of England and Wales, qualified in 1964. He was the founding & Senior Partner of Coopers & Lybrand Malta, which eventually became PriceWaterhouseCoopers where he remained Senior Partner until he retired. Outside of his professional career Norman has been involved in successful business projects within the real estate development, hospitality, catering and manufacturing sectors.

# Advisory Team from Asana Bio Group Israel

## PROF. MOSHE HOD

Chairman

- President of the European Association of Perinatal Medicine
- Director of Maternal Fetal Medicine Division at the Helen Schneider Women's Hospital, Rabin Medical Center, Israel
- Access to the leading medical institutes worldwide

## PROF. LUMIR HANUS

Chief Scientist

- One of the leading Cannabis experts worldwide; he was the first to identify and isolate Anandamide (an endocannabinoid found in the human brain) and is responsible for some of the most cited articles in the Cannabis field.

## DR. SARI SAGIV


VP R&D

- Experience in running clinical trials for Cannabinoid based treatments and has conducted these for leading companies in the sector, including BOL Pharma & Talent Biotech.

## GILAD LIVNI

Chief Agronomist

- 15 years' experience in the Medical Cannabis sector
- Seach: 1 of 8 Israeli government approved license holders
- Valley Agriceuticals: 1 of 5 license holders in New York, USA
- Access to established Medical Cannabis strains



# Capital Structure

## **CAPITAL STRUCTURE**

20,000,000

## **SHARE CLASS**

Common Shares  
No additional share class

## **DEBT**

Company has no debt

## **MINIMAL MONTHLY EXPENDITURE**

Low monthly burn rate coupled with tremendous productivity = highly efficient operations conserving capital for growth and acquisitions.

## **CAPITAL RAISE**

Friends & Family round of CAD \$2.0 million via a non-brokered private placement

## **COMPLIANCE**

Legal: McMillian  
Audit: Manning Elliott LLP  
Accounting: TBD

# Valuation Comps

Company	Company Area of Focus	Market Cap*
Numinus Wellness Inc.	Drug Development / Clinics	\$118M
Compass Pathways PLC.	Supply Chain + R&D	\$3.31B (USD)
Havn Life Sciences Inc.	Drug Development / Clinics	\$14.5M
Optimi Health Corp.	Functional Mushrooms	\$21.99M
Pharma Drug Inc.	Medical Cannabis & Psychedelics	\$13.36M
Field Trip Health Ltd.	Supply Chain & Clinics	\$89M (USD)
<b>Periscope BioScience Corp.</b>	<b>Vertically Integrated Hybrid</b>	<b>\$5M</b>

\*As of February 19, 2022

# The Offering

**Pre Money Valuation: CAD \$5,000,000**

**Current F&F offering: CAD \$2,000,000**

**Minimum Investment: CAD \$5,000**

**Price per share: \$0.25 per common share, each share includes 1 warrant exercisable at CAD \$0.40 for a period of 2 years.**

# Why Invest in Periscope

## FOCUS ON REVENUE AND PROFITABILITY

Periscope targets generating revenue from sales of Cannabis and Psychedelic products by Q3 2022, with additional business lines coming on-stream shortly after. Periscope is laser focused on building revenues and market share today while strategically positioning for the future.

## DISRUPTIVE PRODUCTS & SERVICES

Periscope is focused on acquiring and developing IP, manufacturing technologies, and products that deliver a “best-in-class” offering raising the standard of care in mental health and addictions.

## MANUFACTURING & DISTRIBUTION

Periscope has both the eu-GMP manufacturing capabilities and substantial distribution reach in the EU and North America allowing for streamlined “plug and play” product distribution. LOI’s in place with major pharmacy chains in the EU.

## EXPERIENCED LEADERSHIP

Periscope is founded and led by a team of established business leaders with successful backgrounds in capital markets, international business, product development, and expertise with scaling opportunities in regulated industries.



# Periscope BioScience

For further information or to discuss an opportunity please contact:

**Derek Shepherd | Chief Executive Officer , Co-Founder**

Vancouver, BC, Canada

Direct: 778-512-8895

derek@periscopebio.com

[www.periscopebio.com](http://www.periscopebio.com)